«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

21卷

期数:

2015年03期

页码:

208-211

栏目:

基础医学

出版日期:

2015-05-20

文章信息/Info

Title:

Association between polymorphism of rs798766 and urothelial bladder cancer risk from Han population of Tianjin

文章编号:

1006-8147（2015）03-0208-04

作者:

乔志辉¹; 2; 王仁杰³; 谢万青²; 孙 岩²; 吴长利¹; 2; 胡海龙¹; 2

(1. 天津医科大学第二医院泌尿外科,天津 300211;2. 天津市泌尿外科研究所,天津 300211;3. 太原钢铁（集团）有限公司总医院泌尿外科,太原 030003 )

Author(s):

 QIAO Zhi-hui¹; 2 ; WANG Ren-jie³;   XIE Wan-qin² ;  SUN Yan² ;  WU Chang-li¹; 2 ;  HU Hai-long¹; 2

(1. Department of Urology, The Second Hospital , Tianjin Medical University, Tianjin 300211, China; 2. Tianjin  Institute of  Urology, Tianjin 300211, China; 3. Department of Urology, General Hospital , Taiyuan Iron and Steel( Group)Co., LTD,Taiyuan 030003, China)

关键词:

膀胱尿路上皮癌 ;  单核苷酸多态性 ;  全基因组关联研究 ;  遗传易感性

Keywords:

urothelial bladder cancer;  polymorphism;  genome-wide association studies;  genetic susceptibility

分类号:

R737.14

DOI:

-

文献标志码:

A

摘要:

目的： 探讨rs798766 单核苷酸多态性与天津地区汉族人群膀胱尿路上皮癌发病风险的关系。方法： 采用等位基因特异性PCR技术对363例膀胱尿路上皮癌患者（试验组）和384例对照人群（对照组）的基因型进行分型。结果： 试验组rs798766 T等位基因频率为15.3%，C等位基因频率为84.7%；对照组T等位基因频率为10.5%，C等位基因频率为89.5%，两组T等位基因频率分布存在明显的统计学差异（P=0.006；校正OR=1.53；95%CI为1.13～2.08）；与基因型C/C相比，rs798766 (C/T+T/T)基因型明显增加膀胱尿路上皮癌的发病风险（P=0.006；校正OR=1.61； 95%CI为1.14～2.25）；病理分层分析显示，rs798766 单核苷酸多态性与膀胱癌病理分期、分级无相关性。结论： Rs798766 T等位基因明显增加天津地区汉族人群膀胱尿路上皮癌发病风险，可能是预测天津地区汉族人群膀胱癌发病风险的良好基因标记。

Abstract:

 Objective:To assess the associations between single nucleotide polymorphism (SNP) of rs798766 with urothelial bladder cancer （UBC）risk in a case-control study from Han population of Tianjin. Methods: Genotypes were analyzed using a PCR amplification of specific alleles (PASA) method in 364 patients with UBC and 384 matched healthy controls. Results: The frequency of allele T in patients group was 15.3%, and allele C 84.7%. The frequency of allele T in controls group was 10.5%, and allele C 89.5%. There was a significant difference between the two groups(P=0.006；Adjusted OR=1.53；95%CI=1.13-2.08); Compared with the C/C genotype, rs798766 genotypes (C/T+T/T) could significantly increase the risk of UBC (P=0.006；Adjusted OR=1.61；95%CI=1.14-2.25); Stratification analysis of pathology showed that the association of rs798766 with tumor grade/stage for bladder cancer was not statistically significant. Conclusion: The results indicate that rs798766 T allele could significantly increase the risk of UBC, and may be used as a genetic marker to evaluate the susceptibility for UBC in Han population of Tianjin .

参考文献/References:

[1]Jemal A, Bray F, Center M M, et al. Global ancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69
[2]Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29
[3]Wang M L, Chu H Y, Yan F, et al. Chromosome 4p16.3 variant modify bladder cancer risk in a Chinese population[J]. Carcinogenesis, 2011, 32(6): 872
[4]Yang L, Parkin D M, Li L D, et al. Estimation and projection of the National profile of cancer mortality in China:1991–2005[J]. Br J Cancer, 2004, 90(11): 2157
[5]Murta-Nascimento C, Schmitz-Draeger B J, Zeegers M P, et al. Epidemiology of urinary bladder cancer: from tumor development to patient’s death[J]. World J Urol, 2007, 25(3): 285
[6]Aben K K, Baglietto L, Baffoe-Bonnie A, et al. Segregation analysis of urothelial cell carcinoma[J]. Eur J Cancer, 2006, 42(10): 1428
[7]Murta-Nascimento C, Silverman D T, Kogevinas M, et al. Risk of bladder cancer associated with family history of cancer: Do low-penetrance polymorphisms account for the increase in risk[J]. Cancer Epidemiol Biomarkers Prev, 2007, 16(8): 1595
[8]Cheng L, Maclennan G T, Lopez-Beltran A. Histologic grading of urothelial carcinoma: a reappraisal[J]. Hum Pathol, 2012, 43(12): 2097
[9]Okimoto R, Dodgson J B. Improved PCR amplification of multiple specific alleles(PAMSA)using internally mismatched primers[J]. Biotechniques, 1996, 21(1): 20
[10]Newton C R, Graham A, Heptinstall L E, et al. Analysis of any point mutation in DNA.The amplification refractory mutation system(ARMS)[J]. Nucleic Acids Res, 1989, 17(7): 2503
[11]Bottema C D, Sarkar G, Cassady J D, et al. Polymerase chain reaction amplification of specific alleles:a general method of detection of mutations,polymorphisms,and haplotypes[J]. Methods Enzymol, 1993, 218: 388
[12]Sommer S S, Groszbach A R, Bottema C D. PCR amplification of specific alleles(PASA)is a general method for rapidly detecting known single-base changes[J]. Biotechniques, 1992, 12(1): 82
[13]Kiemeney L A, Sulem P, Besenbacher S A, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer[J]. Nat Genet, 2010, 42(5): U67
[14]Ha G H, Kim J L, Breuer E . Transforming acidic coiled-coil proteins (TACCs) in human cancer[J]. Cancer Lett, 2013, 336(1): 24
[15]Duncan C G, Killela P J, Payne C A, et al. Integrated genomic analyses identify ERRFI1 and TACC3 as lioblastoma-targeted genes[J]. Oncotargetet, 2010, 1(4): 265
[16]Jung C K, Jung J H, Park G S, et al. Expression of transforming acidic coiled-coil containing protein 3 is a novel Independent prognostic marker in non-small cell lung cancer[J]. Pathol Int, 2006, 56(9): 503
[17]Stewart J P, Thompson A, Santra M, et al. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma[J]. Br J Haematol, 2004, 126(1): 72
[18]Kang H N, Wilson C S, Harvey R C, et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children’s Oncology Group study[J]. Blood, 2012, 119(8): 1872
[19]Chakraborty J, Okonta H, Bagalb H, et al. Retroviral gene insertion in breast milk mediated lymphomagenesis[J]. Virology, 2008, 377(1): 100
[20]Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas[J]. Nat Genet, 1999, 23(1): 18
[21]Zuiverloon T C, van der Aa M N, van der Kwast T H, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with Low-Grade Non-Muscle-Invasive bladder cancer[J]. Clin Cancer Res, 2010, 16(11): 3011
[22]Burger M, van der Aa M N, van Oers J M, et al. Prediction of progression of Non-Muscle-Invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study[J]. Eur Urol, 2008, 54(4): 835
[23]Hernández S, López-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in non muscle invasive urothelial bladder carcinomas[J]. J Clin Oncol, 2006, 24(22): 3664
[24]van Rhijn B W, Vis A N, van der Kwast T H, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome[J]. J Clin Oncol, 2003, 21(10): 1912
[25]Billerey C, Chopin D, Aubriot-Lorton M H, et al. Frequent FGFR3mutations in papillary non-invasive bladder(pTa)tumors[J]. J Pathol, 2001, 158(6): 1955
[26]Williams S V, Hurst C D, Knowles M A. Oncogenic FGFR3 gene fusions in bladder cancer[J]. Hum Mol Genet, 2013, 22(4): 795

相似文献/References:

备注/Memo

备注/Memo:

基金项目 国家自然科学基金资助项目（30700834），天津市自然科学基金资助项目（12ZCDZSY16600），天津市应用基础与前沿技术研究计划项目（14JCYBJC26300）

作者简介 乔志辉(1986-)，男，硕士在读，研究方向：单核苷酸多态性与膀胱癌发病风险相关性研究；通信作者：胡海龙，E-Mail：hhllove2004@163.com。

 

常用功能

更新日期/Last Update: 2015-05-27